Data from Codiak’s exoASO™-STAT6 preclinical development program for the treatment of primary and metastatic hepatic cancers published in Science Advances
Codiak BioSciences' exoASO-STAT6 demonstrates potent anti-tumor efficacy by reprogramming tumor-associated macrophages to an M1 phenotype, showing promise as a monotherapy candidate for hepatocellular carcinomas and other cancers. The company plans to initiate Phase 1 clinical trials in the first half of 2022.